Compare YieldMax AI & Tech Portfolio Option Income ETF (GPTY) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax AI & Tech Portfolio Option Income ETF vs Pfizer Inc — how do they compare? YieldMax AI & Tech Portfolio Option Income ETF trades at $43.24, while Pfizer Inc trades at $26.8 (market cap $149.96B). The key difference: Pfizer Inc pays a 6.54% dividend while YieldMax AI & Tech Portfolio Option Income ETF pays none, and Pfizer Inc is trading nearer its 52-week high, YieldMax AI & Tech Portfolio Option Income ETF nearer its low. Which is the better fit depends on your goals.
| GPTY | PFE | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $50.52 | $28.56 |
52-Week Low | $34.73 | $23.60 |
Market Cap | — | $149.96B |
Volume | — | 29,869,932 |
Enterprise Value | — | $201.45B |
Dividend Yield | — | 6.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GPTY trades at $42.99, up 0.79% on the day, with a bullish technical signal from moving averages and ADX indicators, though RSI_6 at 83.06 suggests overbought conditions. The ETF maintains a consistent weekly dividend distribution strategy, with recent payouts ranging from $0.28 to $0.38, highlighting its income-focused approach through option premiums on AI and tech equities.
Outlook remains positive due to strong AI theme exposure and income generation, but risks include reliance on semiconductor momentum and potential NAV erosion from option strategies. Investors benefit from high yield but face volatility tied to tech sector performance.
Pfizer (PFE) trades at $26.62, down 1.59% with a bullish technical signal. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analyst consensus is mixed with 38% buy ratings and a $27.86 price target. Recent news highlights Pfizer's pipeline developments in oncology and obesity treatments, positioning for future growth despite patent cliff concerns.
Pfizer presents a value opportunity with defensive cash flows and dividend yield, but faces patent expiration risks and competitive pressures. The stock trades below analyst targets with strong institutional support, though margin compression and pipeline execution remain key watchpoints for investors seeking pharmaceutical exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About YieldMax AI & Tech Portfolio Option Income ETF
GPTY is an actively managed ETF that seeks to provide current income and capital appreciation by holding a concentrated portfolio of 15 to 30 leading AI and technology companies. It utilizes a variety of options strategies, including selling call options on its underlying holdings, to generate weekly distributions while maintaining direct equity exposure to the growth of the AI sector.
Read more on GPTY →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
